[HTML][HTML] Afatinib in NSCLC with HER2 mutations: results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP)
Introduction Mutations in erb-b2 receptor tyrosine kinase 2 (HER2) oncogene are observed
in approximately 3% of lung adenocarcinomas or mixed tumors with adenocarcinoma …
in approximately 3% of lung adenocarcinomas or mixed tumors with adenocarcinoma …
[HTML][HTML] Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)
R Dziadziuszko, EF Smit, U Dafni, J Wolf… - Journal of Thoracic …, 2019 - jto.org
Introduction Mutations in erb-b2 receptor tyrosine kinase 2 (HER2) oncogene are observed
in approximately 3% of lung adenocarcinomas or mixed tumors with adenocarcinoma …
in approximately 3% of lung adenocarcinomas or mixed tumors with adenocarcinoma …
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).
R Dziadziuszko, EF Smit, U Dafni, J Wolf… - Journal of thoracic …, 2019 - boris.unibe.ch
INTRODUCTION Mutations in erb-b2 receptor tyrosine kinase 2 (HER2) oncogene are
observed in approximately 3% of lung adenocarcinomas or mixed tumors with …
observed in approximately 3% of lung adenocarcinomas or mixed tumors with …
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)
R Dziadziuszko, EF Smit, U Dafni… - Journal of thoracic …, 2019 - pubmed.ncbi.nlm.nih.gov
Introduction Mutations in erb-b2 receptor tyrosine kinase 2 (HER2) oncogene are observed
in approximately 3% of lung adenocarcinomas or mixed tumors with adenocarcinoma …
in approximately 3% of lung adenocarcinomas or mixed tumors with adenocarcinoma …
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)
R Dziadziuszko, EF Smit, U Dafni, J Wolf… - Journal of Thoracic …, 2019 - zora.uzh.ch
INTRODUCTION Mutations in erb-b2 receptor tyrosine kinase 2 (HER2) oncogene are
observed in approximately 3% of lung adenocarcinomas or mixed tumors with …
observed in approximately 3% of lung adenocarcinomas or mixed tumors with …
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).
R Dziadziuszko, EF Smit, U Dafni, J Wolf… - Journal of thoracic …, 2019 - sonar.ch
METHODS NICHE, a single-arm phase II trial using a two-stage Simon's design, explored
the potential of afatinib to control disease in pretreated patients with advanced NSCLC …
the potential of afatinib to control disease in pretreated patients with advanced NSCLC …
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)
R Dziadziuszko, EF Smit, U Dafni, J Wolf… - J. Thorac …, 2019 - kups.ub.uni-koeln.de
Introduction: Mutations in erb-b2 receptor tyrosine kinase 2 (HER2) oncogene are observed
in approximately 3% of lung adenocarcinomas or mixed tumors with adenocarcinoma …
in approximately 3% of lung adenocarcinomas or mixed tumors with adenocarcinoma …
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).
R Dziadziuszko, EF Smit, U Dafni, J Wolf… - Journal of thoracic …, 2019 - folia.unifr.ch
METHODS NICHE, a single-arm phase II trial using a two-stage Simon's design, explored
the potential of afatinib to control disease in pretreated patients with advanced NSCLC …
the potential of afatinib to control disease in pretreated patients with advanced NSCLC …
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).
R Dziadziuszko, EF Smit, U Dafni, J Wolf… - Journal of Thoracic …, 2019 - europepmc.org
INTRODUCTION: Mutations in erb-b2 receptor tyrosine kinase 2 (HER2) oncogene are
observed in approximately 3% of lung adenocarcinomas or mixed tumors with …
observed in approximately 3% of lung adenocarcinomas or mixed tumors with …
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)
R Dziadziuszko, EF Smit, U Dafni, J Wolf… - J. Thorac …, 2019 - kups.ub.uni-koeln.de
Introduction: Mutations in erb-b2 receptor tyrosine kinase 2 (HER2) oncogene are observed
in approximately 3% of lung adenocarcinomas or mixed tumors with adenocarcinoma …
in approximately 3% of lung adenocarcinomas or mixed tumors with adenocarcinoma …